ArticleClinical immunology (Orlando, Fla.)2008
Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis.
Article in Clinical immunology (Orlando, Fla.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01882010 (Leukine), which is not on this map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Leukine (Sargramostim) for Parkinson's Disease
Who cites it
38 citing papers in PubMed, 66 citations in OpenAlex.
- Development of an extended half-life GM-CSF fusion protein for Parkinson's disease.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Regulatory T Cell Therapeutics for Neuroinflammatory Disorders.Critical reviews in immunology · 2022Review
- Granulocyte-macrophage colony-stimulating factor mRNA and Neuroprotective Immunity in Parkinson's disease.Biomaterials · 2021Article
- Neuroprotective Activities of Long-Acting Granulocyte-Macrophage Colony-Stimulating Factor (mPDM608) in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Intoxicated Mice.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Article
- Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- Identification of a Novel OX40LScientific reports · 2018Article
- Advances in autoimmune myasthenia gravis management.Expert review of neurotherapeutics · 2018Review
- A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4Frontiers in immunology · 2018Article
- N-3 polyunsaturated fatty acids restore Th17 and Treg balance in collagen antibody-induced arthritis.PloS one · 2018Article
- Regulatory T cells in multiple sclerosis and myasthenia gravis.Journal of neuroinflammation · 2017Review
- Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial.NPJ Parkinson's disease · 2017Article
- B10 Cell Frequencies and Suppressive Capacity in Myasthenia Gravis Are Associated with Disease Severity.Frontiers in neurology · 2017Article
- Depletion of CD4+ CD25+ regulatory T cells confers susceptibility to experimental autoimmune encephalomyelitis (EAE) in GM-CSF-deficient Csf2-/- mice.Journal of leukocyte biology · 2016Article
- Age-dependent divergent effects of OX40L treatment on the development of diabetes in NOD mice.Autoimmunity · 2016Article
- Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Review
- Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2015Review
- Cytokine modulation correlates with severity of monkeypox disease in humans.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2015Article
- Granulocyte-macrophage colony stimulating factor exerts protective and immunomodulatory effects in cortical trauma.Journal of neuroimmunology · 2015Article
- CD1d(hi)CD5+ B cells expanded by GM-CSF in vivo suppress experimental autoimmune myasthenia gravis.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- GM-CSF-neuroantigen fusion proteins reverse experimental autoimmune encephalomyelitis and mediate tolerogenic activity in adjuvant-primed environments: association with inflammation-dependent, inhibitory antigen presentation.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
We had previously observed that treatment utilizing granulocyte-macrophage colony-stimulating factor (GM-CSF) had profound effects on the induction of experimental autoimmune myasthenia gravis (EAMG), a well-characterized antibody-mediated autoimmune disease. In this study, we show that EAMG induced by repeated immunizations with acetylcholine receptor (AChR) protein in C57BL6 mice is effectively suppressed by GM-CSF treatment administered at a stage of chronic, well-established disease. In addition, this amelioration of clinical disease is accompanied by down-modulation of both autoreactive T cell, and pathogenic autoantibody responses, a mobilization of DCs with a tolerogenic phenotype, and an expansion of regulatory T cells (Tregs) that potently suppress AChR-stimulated T cell proliferation in vitro. These observations suggest that the mobilization of antigen-specific Tregs in vivo using pharmacologic agents, like GM-CSF, can modulate ongoing anti-AChR immune responses capable of suppressing antibody-mediated autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.